Detalhe da pesquisa
1.
Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.
Circulation
; 149(5): 343-353, 2024 01 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37860863
2.
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.
Lancet
; 403(10432): 1141-1152, 2024 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38461841
3.
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
Lancet
; 403(10432): 1153-1163, 2024 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38461843
4.
Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment-Elevation Myocardial Infarction: Results of REAL-TIMI 63B.
Circulation
; 146(12): 907-916, 2022 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36039762
5.
LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease.
Arterioscler Thromb Vasc Biol
; 41(12): 3005-3014, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34706556
6.
Technology-Enabled Clinical Trials: Transforming Medical Evidence Generation.
Circulation
; 140(17): 1426-1436, 2019 10 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31634011
7.
Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus.
Diabetologia
; 62(3): 373-386, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30593607
8.
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Lancet
; 391(10140): 2607-2618, 2018 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-29945727
9.
MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study.
Br J Clin Pharmacol
; 84(10): 2325-2335, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29926478
10.
Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin.
Cardiovasc Diabetol
; 16(1): 113, 2017 09 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-28903775
11.
Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR-TIMI 53 outcome study.
Diabetes Obes Metab
; 19(7): 1045-1050, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28181728
12.
COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES ß-CELL FUNCTION.
Endocr Pract
; 23(3): 258-265, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27849380
13.
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
N Engl J Med
; 369(14): 1317-26, 2013 Oct 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-23992601
14.
Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
Circulation
; 130(18): 1579-88, 2014 Oct 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-25189213
15.
Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective.
Curr Diab Rep
; 15(11): 87, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26370698
16.
Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials.
Cardiovasc Diabetol
; 13: 33, 2014 Feb 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-24490835
17.
Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus.
Diabetes Metab Res Rev
; 30(7): 556-69, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24376173
18.
Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy.
Endocr Pract
; 20(11): 1187-97, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25370334
19.
Medical cannabis for pain management in patients undergoing chronic hemodialysis: randomized, double-blind, cross-over, feasibility study.
Clin Kidney J
; 16(4): 701-710, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37007688
20.
Nasopharyngeal Viral Load Is the Major Driver of Incident Antibody Immune Response to SARS-CoV-2 Infection.
Open Forum Infect Dis
; 10(12): ofad598, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38111750